◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY
Rubicon Research Limited (RUBICON)
来自官方财务报表的收入、利润与现金流历史。
Healthcare · 华尔街（美国） · 最近更新： 2026-09-20
Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. The company develops products in the areas of analgesics/pain management, cardiovascular system, central nervous system, hypokalemia, skeletal muscle relaxants, nicotine replacement therapy, gastrointestinal, metabolic, and immunosuppressant.
关键数据
- 市值: ₹289 billion
- 收入（截至 2026-03-31 财年）: ₹17.3B
- 净利润: ₹2.5B
- 毛利率: 66.2%
- 净利率: 14.3%
查看交互式图表与完整报表 →
年度利润表
| 利润表 | 2026-03-31 | 2025-03-31 |
|---|
| 总收入 | ₹17.3B | ₹12.7B |
| 毛利 | ₹11.5B | ₹8.8B |
| 营业利润（EBIT） | ₹3.6B | ₹2.2B |
| 净利 | ₹2.5B | — |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 RUBICON 交互式查看器。 /companies/us/RUBICON
类似公司
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms
TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.